Kemi Olugemo M.D., Chief Medical Officer at Korro Bio, brings over 20 years of clinical research and biopharmaceutical industry experience, with deep expertise in nucleic acid therapies, biologics and other modalities.
Prior to joining Korro, Dr. Olugemo was Vice President Global Clinical Development at Ultragenyx Pharmaceutical, and has held positions of increasing responsibility at Parexel, Ionis Pharmaceuticals and Laronde. Kemi led clinical development and operations for multiple global programs in rare and common diseases across an array of therapeutic areas, resulting in approvals in global markets.
Kemi has a passion for professional development, and health & gender equity, and is the recipient of the Zuckerberg College of Health Sciences Alumni Award from the University of Massachusetts in Lowell, Leadership in Action Award from Women of Color in Pharma, and the 2023 Extraordinary Women Advancing Healthcare in Massachusetts Award from the Women’s Edge.
Kemi completed her medical training and Neurology Residency at the University of Maryland School of Medicine, and an additional Fellowship in Neuroimmunology & Multiple Sclerosis at the Maryland Center for MS. She is a Fellow of the American Academy of Neurology.